Treatment and outcome of 370 cases with spontaneous or post-laser twin anemia-polycythemia sequence managed in 17 fetal therapy centers.


Journal

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
ISSN: 1469-0705
Titre abrégé: Ultrasound Obstet Gynecol
Pays: England
ID NLM: 9108340

Informations de publication

Date de publication:
09 2020
Historique:
received: 18 12 2019
revised: 23 03 2020
accepted: 25 03 2020
pubmed: 16 4 2020
medline: 8 9 2021
entrez: 16 4 2020
Statut: ppublish

Résumé

To investigate the antenatal management and outcome in a large international cohort of monochorionic twin pregnancies with spontaneous or post-laser twin anemia-polycythemia sequence (TAPS). This study analyzed data of monochorionic twin pregnancies diagnosed antenatally with spontaneous or post-laser TAPS in 17 fetal therapy centers, recorded in the TAPS Registry between 2014 and 2019. Antenatal diagnosis of TAPS was based on fetal middle cerebral artery peak systolic velocity > 1.5 multiples of the median (MoM) in the TAPS donor and < 1.0 MoM in the TAPS recipient. The following antenatal management groups were defined: expectant management, delivery within 7 days after diagnosis, intrauterine transfusion (IUT) (with or without partial exchange transfusion (PET)), laser surgery and selective feticide. Cases were assigned to the management groups based on the first treatment that was received after diagnosis of TAPS. The primary outcomes were perinatal mortality and severe neonatal morbidity. The secondary outcome was diagnosis-to-birth interval. In total, 370 monochorionic twin pregnancies were diagnosed antenatally with TAPS during the study period and included in the study. Of these, 31% (n = 113) were managed expectantly, 30% (n = 110) with laser surgery, 19% (n = 70) with IUT (± PET), 12% (n = 43) with delivery, 8% (n = 30) with selective feticide and 1% (n = 4) underwent termination of pregnancy. Perinatal mortality occurred in 17% (39/225) of pregnancies in the expectant-management group, 18% (38/215) in the laser group, 18% (25/140) in the IUT (± PET) group, 10% (9/86) in the delivery group and in 7% (2/30) of the cotwins in the selective-feticide group. The incidence of severe neonatal morbidity was 49% (41/84) in the delivery group, 46% (56/122) in the IUT (± PET) group, 31% (60/193) in the expectant-management group, 31% (57/182) in the laser-surgery group and 25% (7/28) in the selective-feticide group. Median diagnosis-to-birth interval was longest after selective feticide (10.5 (interquartile range (IQR), 4.2-14.9) weeks), followed by laser surgery (9.7 (IQR, 6.6-12.7) weeks), expectant management (7.8 (IQR, 3.8-14.4) weeks), IUT (± PET) (4.0 (IQR, 2.0-6.9) weeks) and delivery (0.3 (IQR, 0.0-0.5) weeks). Treatment choice for TAPS varied greatly within and between the 17 fetal therapy centers. Antenatal treatment for TAPS differs considerably amongst fetal therapy centers. Perinatal mortality and morbidity were high in all management groups. Prolongation of pregnancy was best achieved by expectant management, treatment by laser surgery or selective feticide. © 2020 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.

Identifiants

pubmed: 32291846
doi: 10.1002/uog.22042
pmc: PMC7497010
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

378-387

Investigateurs

J M Middeldorp (JM)
M C Haak (MC)
F J C M Klumper (FJCM)
J Akkermans (J)
H Delagrange (H)
V Pandya (V)
S Faiola (S)
R Favre (R)
S R Hobson (SR)
C Rodo (C)
B Thilaganathan (B)
R Papanna (R)
P Greimel (P)
M Tavares de Sousa (M)
A Carlin (A)
K A Gladkova (KA)
J A Copel (JA)

Informations de copyright

© 2020 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.

Références

Ultrasound Obstet Gynecol. 2015 Oct;46(4):432-6
pubmed: 26094734
Prenat Diagn. 2010 Mar;30(3):251-5
pubmed: 20087909
Behav Brain Res. 1992 Jul 31;49(1):1-6
pubmed: 1388792
Ultrasound Obstet Gynecol. 2014 Sep;44(3):304-10
pubmed: 24706478
J Clin Med. 2020 Jun 05;9(6):
pubmed: 32517071
Clin Perinatol. 1989 Jun;16(2):387-411
pubmed: 2663308
N Engl J Med. 2004 Jul 8;351(2):136-44
pubmed: 15238624
Fetal Diagn Ther. 2015;38(3):170-8
pubmed: 25790745
Ultrasound Obstet Gynecol. 2013 Jun;41(6):702-6
pubmed: 23124777
Am J Obstet Gynecol. 2008 Nov;199(5):514.e1-8
pubmed: 18533114
Am J Obstet Gynecol. 2020 Jul 27;:
pubmed: 32730900
Ultrasound Obstet Gynecol. 2014 Sep;44(3):316-21
pubmed: 24753027
J Obstet Gynaecol Can. 2019 Jul;41(7):981-991
pubmed: 31230662
Lancet. 2014 Jun 21;383(9935):2144-51
pubmed: 24613024
Ultrasound Obstet Gynecol. 2020 Jan;55(1):39-46
pubmed: 31432580
J Vis Exp. 2011 Sep 05;(55):e3208
pubmed: 21912373
Twin Res Hum Genet. 2016 Jun;19(3):222-33
pubmed: 27068715
Ann Surg. 1978 Jan;187(1):1-7
pubmed: 413500
Fetal Diagn Ther. 2010;27(4):181-90
pubmed: 20339296
Am J Obstet Gynecol. 2006 Mar;194(3):796-803
pubmed: 16522415
Placenta. 2007 Jan;28(1):47-51
pubmed: 16516289
Arch Ophthalmol. 1984 Aug;102(8):1130-4
pubmed: 6547831
Arch Dis Child. 1981 Dec;56(12):900-4
pubmed: 7332336

Auteurs

L S A Tollenaar (LSA)

Department of Obstetrics, Division of Fetal therapy, Leiden University Medical Center, Leiden, The Netherlands.

F Slaghekke (F)

Department of Obstetrics, Division of Fetal therapy, Leiden University Medical Center, Leiden, The Netherlands.

L Lewi (L)

Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Belgium.

Y Ville (Y)

Department of Obstetrics and Maternal-Fetal Medicine, Hôpital Necker-Enfants Malades, AP-HP, Paris, France.

M Lanna (M)

Fetal Therapy Unit 'U. Nicolini', Vittore Buzzi Children's Hospital, University of Milan, Milan, Italy.

A Weingertner (A)

Department of Obstetrics and Gynecology, Strasbourg University Hospital, Strasbourg Cedex, France.

G Ryan (G)

Fetal Medicine Unit, Ontario Fetal Centre, Mount Sinai Hospital, University of Toronto, Toronto, Canada.

S Arévalo (S)

Maternal Fetal Medicine Unit, Department of Obstetrics, Vall d'Hebron University Hospital, Barcelona, Spain.

A Khalil (A)

Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust, University of London, London, UK.
Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK.

C O Brock (CO)

The Fetal Center, Department of Obstetrics, Children's Memorial Hermann Hospital, Gynecology and Reproductive Sciences, UT Health, McGovern Medical School, University of Texas, Houston, TX, USA.

P Klaritsch (P)

Division of Obstetrics and Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria.

K Hecher (K)

Department of Obstetrics and Fetal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

G Gardener (G)

Department of Maternal Fetal Medicine, Mater Mothers' Hospital, South Brisbane, Queensland, Australia.

E Bevilacqua (E)

Department of Obstetrics and Gynecology, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium.

K V Kostyukov (KV)

Acad. V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation, Moscow, Russia.

M O Bahtiyar (MO)

Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, CT, USA.

M D Kilby (MD)

Fetal Medicine Centre, Birmingham Women's and Children's Foundation Trust, University of Birmingham, Birmingham, UK.

E Tiblad (E)

Center for Fetal Medicine, Karolinska University Hospital, Stockholm, Sweden.

D Oepkes (D)

Department of Obstetrics, Division of Fetal therapy, Leiden University Medical Center, Leiden, The Netherlands.

E Lopriore (E)

Department of Pediatrics, Division of Neonatology, Leiden University Medical Center, Leiden, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH